Hypoglycemia, although often unrecognized or discussed, is the most frequent side effect of insulin and can increased risk of adverse outcomes, cardiovascular events, and death, and has a significant impact on patients’ quality of life. In this expert brief, Dr. Ronald Goldenberg and Dr. Gihane Zarifa will discuss technologies that can help patients and clinicians identify and track glycemic variability and reduce hypoglycemic events. They will also address the newer, long-lasting insulins that have been shown to result in more stable control of fasting glucose levels with lower risk of hypoglycemia, especially nocturnal hypoglycemia.
Expert Brief #2: New Basal Insulins Reduce the Incidence of Hypoglycemia
CAN-eng
$0
gratuit
Mainpro+
20 mins
Endocrinology
0.25 Credits
Description du cours
Détails du cours
Date d'expiration : 2022-05-10
Métiers: Médecin
Faculté
Ronald Goldenberg, MD, FRCPC, FACE
Gihane Zarifa, MD, CCFP, FCFP, MSc
Chandi Chandrasena, MD, CCFP, FCFP
James Kim, MD, MBBCh, PgDip
Upender Mehan, MD, CCFP, FCFP
Accréditation
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.25 Mainpro+ Credit.
Objectif(s) d'apprentissage
Upon completion of this continuing education program, participants will be better able to:
- Recognize the prevalence and incidence of hypoglycemia in patients with type 2 diabetes treated with insulin;
- Explain how continuous glucose monitoring can uncover hypoglycemia/hyperglycemia and glycemic variability;
- Discuss the reduction of hypoglycemia seen with the newer longer-acting basal insulins.